On May 4, 2026, CNS Pharmaceuticals, Inc. reported that it entered into a Securities Purchase Agreement to raise approximately $22.5 million by selling 650,000 shares at $2.30 each and warrants for additional shares. The company also announced the appointment of Michal Fisher to its Board of Directors following the resignation of Jerzy Gumulka.